key: cord-0040598-90i6lsww authors: Hurst, John R.; Wedzicha, Jadwiga A. title: Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease date: 2009-05-15 journal: Clinical Respiratory Medicine DOI: 10.1016/b978-032304825-5.10039-x sha: 3798206496816a72a8c786d19ea6fe9b442dd540 doc_id: 40598 cord_uid: 90i6lsww nan Chronic obstructive pulmonary disease (COPD) is the fifth most common cause of death in the world, has an increasing mortality rate, and much of the morbidity and mortality relate to episodes of symptom deterioration (i.e., acute exacerbations [AEs] ) that punctuate the course of disease. AEs of COPD account for approximately one in ten emergency medical admissions to hospital, and the in-hospital mortality is 10%. AEs are responsible for 70% of the direct costs attributable to COPD. AEs generally become both more frequent and more severe as the severity of the underlying COPD progresses. On average, patients with moderate to severe COPD, typical of those attending secondary care, will have between one and two AEs requiring additional treatment annually. There are, however, large differences in the annual AE incidence rates of individual patients, and those prone to more frequent AEs experience a particular burden of disease as outlined in Figure 39 -1. The factors predisposing some patients to frequent AEs are poorly understood but may include daily bronchitic symptoms, greater severity of underlying disease, greater airway inflammation in the stable state, a predisposition to acquiring respiratory viral infection, and/or the presence of lower airway bacterial colonization (described later). PATHOPHYSIOLOGY COPD has been defined by the World Health Organization as a disease state characterized by airflow limitation that is progressive, not fully reversible, and associated with an abnormal inflammatory response to noxious particles or gases. Airway inflammation is even greater at the time of AE, and the assumption has been made that this additional inflammation provokes symptoms such as worsening dyspnea and sputum production by mechanisms relating to airway tone, airway wall edema, and mucus production. The resultant airtrapping increases the work of breathing and causes additional impairment to respiratory muscle function. Triggers of increased airway inflammation are, therefore, considered to be the most common causes of AEs, predominantly tracheobronchial infection and with a lesser role for pollutants. The effects of increased inflammation at AE require further clarification, however, because a direct relationship between the clinical severity of the AE and the degree of airway inflammation has never been conclusively demonstrated. Defining the role of airway infection in causing AEs is not a simple task. Recent advances in molecular biology have enabled the isolation of respiratory viruses and potentially pathogenic bacteria from the airways of many patients during exacerbations. The most common organisms identified are listed in Table 39 -1. Patients with more severe underlying disease, however, are also colonized with bacteria when in their stable state. The presence of an organism at AE does not, therefore, imply a role in causing that exacerbation. More recently, it has been suggested that a change in the colonizing bacterial strain may be the precipitating event. However, not all strain changes are associated with an AE, and not all AEs are associated with strain change. Reflecting this, and as discussed later, antibiotics may not be of universal benefit during AEs. Rhinovirus is the most commonly identified viral pathogen, and consequently, AEs are more common during the winter months when viral circulation in the community is higher. The role of atypical organisms such as Chlamydia and Mycoplasma species remains unclear. Large epidemiologic studies link increases in pollutant levels with increases in hospital admission for respiratory disease. PM 10 (particulate matter less than 10 mm in size) appear particularly important. It is possible that pollutants and microorganisms may interact to amplify the risk of exacerbation. It has recently been recognized that COPD is associated with systemic inflammation, and there is now ample evidence to demonstrate that systemic inflammation increases during AEs. This may be important given the associations between cardiovascular death and raised systemic inflammatory markers and the finding that many patients with COPD die from cardiovascular disease. This systemic inflammation is thought to represent "spill over" from the lung. Understanding the pathophysiology of AEs promotes an appreciation of the rationale for the various therapies used: bronchodilators may be helpful for increased bronchoconstriction and hyperinflation; corticosteroids may reduce airway inflammation; and antibiotics may be appropriate in those AEs caused by bacteria (although making this distinction is difficult). This concept is illustrated in Figure 39 -2, and the various therapeutic strategies are described in further detail in the following sections. The cardinal feature of an AE is an increase in respiratory symptoms beyond that which is usual for the patient. Typically, such symptoms include dyspnea, sputum production, sputum purulence, cough, and wheeze, perhaps accompanied by upper respiratory tract symptoms (such as rhinorrhea), peripheral edema, and/or confusion. Clinical signs are nonspecific but may include tachycardia, tachypnea, cyanosis, the use of accessory respiratory muscles, polyphonic expiratory wheeze or crackles on auscultation, an abnormal mental status, elevated jugular venous pressure, edema, and other manifestations of cor pulmonale. AEs are very heterogeneous events, and the clinical features vary widely. Patients with mild underlying disease may experience no more than a troublesome worsening of symptoms, whereas those with more severe COPD are at significant risk of respiratory failure. Furthermore, other conditions occurring in patients with underlying COPD may mimic or complicate exacerbations. Proper assessment, as described below, is therefore important. An AE of COPD is a clinical syndrome, and, as such, there is no confirmatory diagnostic test. Although there has been controversy about the exact definition of AE, and although such differences may be important when interpreting the results of various studies, it is now widely accepted that an AE may be defined as a sustained worsening of a patient's symptoms that is acute in onset, beyond day-to-day variation, and that may necessitate a change in therapy. Although laboratory investigations are not helpful in the diagnosis of AEs, diagnostic tests are of value in assessing the severity of the event and in excluding other conditions that may mimic or complicate the syndrome. Such diagnoses include pneumonia, pneumothorax, pulmonary embolus, and cardiac failure, and appropriate investigations would, therefore, include a chest radiograph, electrocardiogram, oxygen saturations and/ or arterial blood gas analysis, and simple venous blood tests, including full blood count, urea and electrolytes, and C-reactive protein. Spirometry is not generally helpful, because absolute values may be misleading, changes at exacerbation are small, and patients who are acutely dyspneic may have difficulty performing the maneuvers accurately. Sputum microscopy and culture may help to refine empiric antibiotic therapy in those not improving or in those with resistant Pseudomonas infection, but the role of microbiologic studies in the initial evaluation has not been clarified. For those mild exacerbations that respond to an increase in inhaled bronchodilators alone, further investigation may not be warranted. There is no accepted method of assessing exacerbation severity. Quantifying changes in symptoms or lung function is not generally helpful and is difficult to achieve, because it requires knowledge of the patient at baseline. Consequently, the degree of health care utilization has been used as a surrogate assessment of severity: mild exacerbations are defined as those that require no more than an increase in inhaled bronchodilators, moderate exacerbations as those requiring antibiotics and or corticosteroids in the community, and severe exacerbations as those requiring hospital admission. pH is the best indicator of an acute change in alveolar ventilation, and most exacerbations associated with respiratory failure will require hospital assessment. The decision to admit a patient to the hospital is, however, dependent on more than the severity of the exacerbation itself and would include, for example, the patient's social circumstances and the support available to the patient at home. The principles of therapy at the time of an AE are twofold: to modify the course of the event and to support respiratory function while such disease-modifying therapies are able to act. Treatment is given in proportion to the clinical severity of the event, and the sequential approach is illustrated in Figure 39 -3. Many published guidelines exist to guide appropriate therapy, including recent evidence-based statements from the UK National Institute of Clinical Evidence (NICE). Attention to comorbidities is also important, and in the recovery phase, one should consider interventions that may reduce the risk of subsequent exacerbations. An increase in the dose or frequency of inhaled short-acting bronchodilators is the mainstay of therapy. There is little to choose from in terms of bronchodilator effect between the b 2 -agonist salbutamol (albuterol) and the anticholinergic drug ipratropium bromide. Although often used in combination, there is little evidence to suggest an additive benefit. There is also no evidence that administering the medications by nebulization is any more effective than by a metered-dose inhaler and large-volume spacer. However, nebulizers are often preferred in dyspneic patients. Nebulizers for COPD should be driven on compressed air rather than oxygen because of concern for the effect of high alveolar oxygen tensions on ventilationperfusion relationships. Patients prescribed long-acting bronchodilators could continue this therapy, but there is little evidence to support introducing long-acting agents during an AE, and short-acting drugs are preferred. The recommended approach is, therefore, to increase the dose and or frequency of either a short-acting b 2 -agonist or an anticholinergic, with both drugs used together in the event of inadequate clinical response. Systemic corticosteroids are indicated in all but the mildest of exacerbations that respond to an increase in inhaled bronchodilators alone. A number of randomized trials, now summarized in systematic reviews, demonstrate a more rapid improvement in FEV 1 after administration of steroids, although effects on outcomes such as oxygenation, hospitalization, and length of hospital stay are more variable, and an effect on mortality has not been documented. Guidelines vary in their specific recommendations, generally suggesting oral prednisone at a dose between 30 and 40 mg for between 10 and 14 days. Prolonged courses are not of additional benefit (and increase the risk of side effects), and there is no evidence to suggest that tapering the dose is advantageous. Many physicians choose to give the first dose intravenously. Nebulized budesonide results in similar improvements in lung function to oral dosing but is more expensive. Intriguingly, the use of systemic steroids may delay the time to subsequent exacerbation, and although there is no role for the initiation of inhaled steroids at exacerbation, inhaled corticosteroids also have an important role in exacerbation prevention as discussed further in the following. The seminal work on antibiotics at exacerbation, by Anthonisen and colleagues, demonstrated benefit only when patients had an increase in at least two of the following three symptoms: breathlessness, sputum volume, and sputum purulence. Sputum purulence reliably indicates the presence of bacteria at exacerbation. A meta-analysis of the six sufficiently welldesigned randomized trials by Saint and colleagues confirmed a small, but statistically significant, benefit in favor of antibiotics. Local resistance patterns and antibiotic policies will dictate the choice of drug, but coverage should include the common pathogens Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. An oral aminopenicillin, macrolide, or tetracycline is, therefore, an appropriate empiric choice. Comparative data across drug classes are sparse. Intravenous antibiotics are rarely required. There are little data on the optimal duration of therapy. Oxygen is indicated to correct the hypoxemic respiratory failure that may occur with AEs. Hypoxemia is due to a combination of increased ventilation-perfusion mismatch and alveolar hypoventilation. Oxygen should be administered in a controlled manner with monitoring of arterial blood gas tensions or saturations to avoid CO 2 retention and the development of hypercapnic respiratory failure that may occur in a portion of patients. Studies have shown little risk of hypercapnia if oxygen is titrated to a maximum saturation of 90-92%. Failure to correct hypoxemia to > 90% with FiO 2 > 40% suggests the presence of additional pathology such as pulmonary embolus. Achieving adequate oxygenation only at the expense of rising PaCO 2 or falling pH is an indication for ventilatory support. Venturi masks provide a more reliable FiO 2 than nasal cannulae, but the latter may be better tolerated. Noninvasive ventilation (NIV) refers to the provision of ventilatory support by means of a nasal or full-face mask in the absence of an endotracheal tube. There is now considerable evidence supporting the use of NIV for patients with hypercapnic respiratory failure caused by AEs. The benefit in mortality with additional reduction in hospital stay, complications, and cost may largely be attributed to the reduced need for sedation, intubation, and invasive ventilation. In addition, and in contrast to invasive ventilation, NIV may be used earlier and intermittently, which, therefore, facilitates communication, nutrition, and physiotherapy. NIV is usually administered as pressure-cycled bilevel positive airway pressure in which the inspiratory and expiratory pressures may be independently varied. NIV is not, however, a substitute for invasive ventilation when the latter is required. Therefore, a plan of management should be made with regard to suitability for invasive ventilation should NIV fail. In addition, some patients may have relative contraindications to NIV or respiratory failure of such severity that they should be immediately assessed for invasive ventilation. The indications and relative contraindications for NIV are provided in Table 39 -2. Most, but not all, patients suitable for NIV are able to tolerate the treatment. The application of a nasal mask for NIV at exacerbation is illustrated in Figure 39 -4. The primary indications for invasive ventilation at exacerbation of COPD are severe hypoxia or respiratory acidemia (pH < 7.26) in a patient unsuitable for, or failing, NIV. However, although data suggest that patients with COPD have similar outcomes after invasive ventilation to that seen in patients with respiratory failure from other causes, the decision to institute invasive ventilation should consider the prior functional status of the patient, the severity of the current and underlying illness, the degree of reversibility of the present deterioration, the presence and severity of comorbidities, and the wishes of the patient and their families or other caregivers. Mortality after invasive ventilation is approximately 20%, and weaning from the ventilator can be challenging. This is a further setting in which NIV may be valuable. The aim of ventilation is to support gas exchange and respiratory muscle function until other therapies have had sufficient time to be effective. In such circumstances, corticosteroids and antibiotics are usually given parenterally, and bronchodilator drugs may be added to the ventilator circuit from an inhaler and spacer. Methylxanthine drugs such as theophylline have a variety of potentially beneficial effects on respiratory and cardiac function, yet, randomized, controlled trials have failed to show any benefit in lung function or symptoms during exacerbations. Despite this, and in addition to well-recognized problems with drug interactions, side effects, and a narrow therapeutic range necessitating the monitoring of drug levels, theophyllines are still sometimes used in patients who are not demonstrating sufficient progress on otherwise maximal therapy. One action of theophyllines is as phosphodiesterase (PDE) inhibitors, and newer, selective PDE 4 inhibitors are currently being tried (although initial results have been disappointing). There are no data to support the use of intravenous salbutamol for exacerbation of COPD. Side effects are more common than with the inhaled route, and routine use is not recommended. Although exacerbations are often associated with an increased volume or tenacity of sputum, there is currently no firm evidence supporting the use of mucolytic drugs to treat AEs of COPD. There is also no evidence to support strategies aimed at facilitating expectoration such as physiotherapy or saline nebulization (although this largely reflects an absence of evidence rather than evidence supporting the absence of benefit). Cough suppressants are contraindicated. Central respiratory stimulants such as intravenous doxapram have now been all but superseded with the availability of NIV, a therapy that is clearly superior in the management of hypercapnic respiratory failure. A limited role for doxapram may remain if NIV is not appropriate, as a bridge to NIV, or (with specialist advice) in conjunction with NIV. The use of doxapram is often limited by side effects, especially agitation, and any potential benefits do not appear to persist beyond 48 h. Although intravenous magnesium may be an effective bronchodilator in exacerbations of asthma, there are no convincing data supporting its effectiveness in AE of COPD, and its routine use is not recommended. Heliox (a mixture of helium and oxygen) has a lower viscosity than air and may, therefore, reduce the work of breathing. However, there remains no evidence of benefit in treating AEs of COPD. Other supportive measures that should be instituted include appropriate attention to fluid balance and consideration of prophylaxis against venous thromboembolism. Finally, for patients not responding to maximal therapy or for those in whom escalation is inappropriate, a range of palliative approaches to achieve symptom control should be considered. By use of analysis of symptoms and lung function changes, the median length of an exacerbation is approximately 7-10 days, although there is wide variability, and a proportion of exacerbations take considerably longer to improve. Some patients appear never to fully recover to their preexacerbation lung function. Those patients admitted to the hospital have an inhospital mortality of approximately 10%, and for patients with hypercapnic respiratory failure, the mortality approaches 50% at 2 years. Some patients may be suitable for early supported discharge schemes. Although these are associated with similar outcomes, they appear no more cost-effective than standard care. Given the importance of AEs and having managed the acute event, it is important to consider instituting a range of preventative measures to reduce the risk of future AEs. There is accumulating evidence to suggest that a number of classes of medications reduce the incidence of AEs. These include the long-acting b 2 -agonists, long-acting anticholinergics, and inhaled corticosteroids (at least for those with moderately severe underlying disease). Combination therapy with longacting b 2 -agonists and inhaled corticosteroids appears superior to the use of either component alone, and this combination may also have a mortality benefit. Oral corticosteroids are ineffective at preventing exacerbations, and because they also have no effect on other outcomes measures, they are not indicated in stable COPD. Ongoing trials are reexamining the role of antibiotics in reducing exacerbation frequency; there is some existing evidence that these drugs may be effective, but many existing trials included patients with simple chronic bronchitis, the drugs used were older, and any benefit must be balanced against the possibility of promoting drug resistance. Macrolides hold particular promise given their recognized antiinflammatory action. Vaccinations against influenza and S. pneumoniae are recommended. Pulmonary rehabilitation has also been shown to reduce hospitalization in patients with COPD. Furthermore, early treatment has been shown to reduce exacerbation length, and this might be included in a patient education program. There are, therefore, a variety of measures that may be instituted to reduce the number and consequences of exacerbations. For this reason and for further assessment of patients who presented in respiratory failure, it is usually appropriate to review patients in an ambulatory care setting after an admission with acute exacerbation. Recently, there has been increasing research focusing on AEs of COPD, but we still understand little about the relationships between AEs and bacterial type and load or how bacterial and viral pathogens might interact. More effective antiinflammatory agents are required, and the role of antibiotics in preventing exacerbations is unclear. We currently have no effective interventions targeting viral pathogens, especially rhinovirus. Finally, it is now recognized that COPD is associated with systemic inflammation that may cause considerable cardiovascular comorbidity, and ways to assess and manage this may also lead to a reduction in the number or impact of exacerbations. World Health Organization (WHO) Global Initiative for Obstructive Lung Disease (GOLD) resources ERS) standards for the diagnosis and treatment of COPD. www.ersnet.org United Kingdom National Institute for Clinical Excellence (NICE) COPD guidelines Cochrane Airways Group (up-to-date, accurate systematic reviews and meta-analyses) Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease Outcomes following acute exacerbations of severe chronic obstructive pulmonary disease Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease. Cochrane systematic review and meta-analysis Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis Time course and recovery of exacerbations in chronic obstructive pulmonary disease New strains of bacteria and exacerbations of chronic obstructive pulmonary disease Acute exacerbations of chronic obstructive pulmonary disease